NCT03127514Phase 2Completed

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2019-09-25Actual
Enrollment · participants137Actual
Source updated2024-05-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.